- Home
- NTLA vs NAGE Comparison
NTLA vs NAGE Comparison
Compare NTLA & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- NAGE
- Stock Information
- Founded
- NTLA 2014
- NAGE 1999
- Country
- NTLA United States
- NAGE United States
- Employees
- NTLA N/A
- NAGE N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- NTLA Health Care
- NAGE Health Care
- Exchange
- NTLA Nasdaq
- NAGE Nasdaq
- Market Cap
- NTLA 710.1M
- NAGE 594.0M
- IPO Year
- NTLA 2016
- NAGE N/A
- Fundamental
- Price
- NTLA $8.12
- NAGE $8.95
- Analyst Decision
- NTLA Buy
- NAGE Strong Buy
- Analyst Count
- NTLA 19
- NAGE 1
- Target Price
- NTLA $38.26
- NAGE $11.00
- AVG Volume (30 Days)
- NTLA 3.2M
- NAGE 821.9K
- Earning Date
- NTLA 05-08-2025
- NAGE 05-07-2025
- Dividend Yield
- NTLA N/A
- NAGE N/A
- EPS Growth
- NTLA N/A
- NAGE N/A
- EPS
- NTLA N/A
- NAGE 0.18
- Revenue
- NTLA $45,569,000.00
- NAGE $107,925,000.00
- Revenue This Year
- NTLA N/A
- NAGE $21.53
- Revenue Next Year
- NTLA N/A
- NAGE $20.87
- P/E Ratio
- NTLA N/A
- NAGE $50.01
- Revenue Growth
- NTLA N/A
- NAGE 29.77
- 52 Week Low
- NTLA $5.90
- NAGE $2.31
- 52 Week High
- NTLA $28.18
- NAGE $9.50
- Technical
- Relative Strength Index (RSI)
- NTLA 50.39
- NAGE N/A
- Support Level
- NTLA $7.21
- NAGE N/A
- Resistance Level
- NTLA $9.27
- NAGE N/A
- Average True Range (ATR)
- NTLA 0.61
- NAGE 0.00
- MACD
- NTLA 0.02
- NAGE 0.00
- Stochastic Oscillator
- NTLA 44.20
- NAGE 0.00
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.